Gal-3 y ST2 como biomarcadores: un paso al frente en el pronóstico de la Insuficiencia Cardiacá

Gal-3 and ST2 Biomarkers - A Step Forward in Heart Failure Prognostication

Mário Barbosa, MD, MSc1, Andreia Matos, MSc2,3,4,5, Manuel Bicho, MD, PhD2,6, Luiz Menezes Falcão, MD, PhD6,7

1Department of Internal Medicine, Hospital Luísíadas Lisboa, Lisbon, Portugal. 2Genetics Laboratory and Environmental Health Institute-ISAMB, Lisbon, Portugal. 3Instituto de Investigación Científico Bento da Rocha Cabral, Lisbon, Portugal. 4YS-Instituto de Investigación e Inovação em Saúde/INEB-Institute of Biomedical Engineering, University of Porto, Porto, Portugal. 5Abel Salazar Institute for the Biomedical Sciences (ICBAS), University of Porto, Portugal. 6Department of Internal Medicine, Santa Maria Hospital, Lisbon, Portugal. 7Lisbon Faculty of Medicine, Lisbon, Portugal.

ABSTRACT

Aims: The American College of Cardiology (ACA)/ American Heart Association (AHA) granted Galectin-3 (Gal-3) and Suppression of Tumorigenicity 2 (ST2) evaluation a class II recommendation for HF prognosis, as an adjunctive to conventional clinical risk factors and natriuretic peptides dosing in 2013. However, in Europe this endorsement is not valid. The purpose of this study was to study the association of Gal-3 and ST2 collected at-admission with early (defined as the period of 90 days post-discharge) rehospitalization and overall mortality, and end of follow-up overall mortality in HF patients. Additionally, aminoterminal B-type natriuretic peptide (NT-proBNP) at admission was considered to test if a multi-marker strategy could yield supplementary information.

Material and Methods: Gal-3, ST2 and NT-proBNP were assessed in patients hospitalized with acute decompensated HF in class III or IV of New York Heart Association (NYHA). Univariate Cox proportional hazard model was used to assess the relationship between variables and outcomes. Since there are no standardized cut-offs for Gal-3 and ST2, the multiclass Area Under the Curve Receiver-Operator Characteristic (AUCROC) as defined by Hand and Till was used to evaluate the overall performance of each biomarker as a predictor of the outcomes.

Results: We followed 65 patients for a median of 13.7 (Q1-Q3 6.7-18.9) months. Gal-3 correlated with short-term rehospitalization (HR: 9.886, 95% CI: 2.027-48.214, P-value=0.005), short-term mortality (HR: 13.731, 95% CI: 1.650-114.276, P-value=0.015) and end of follow-up mortality (HR: 4.492, 95% CI: 1.594-12.656, P-value=0.004). The association of elevated NT-proBNP determinations increased the risk of short-term rehospitalization (HR: 11.985, 95% CI: 1.962-73.218, P-value=0.007) and end of follow-up mortality (HR: 78.025, 95% CI: 7.592-801.926, P-value<0.001). ST2 correlated with end of follow-up mortality (HR: 4.846, 95% CI: 1.396-16.825, P-value=0.013). The risk further increased if NT-proBNP (HR: 5.953, 95% CI: 1.683-21.055, P-value=0.006) or Gal-3 determinations (HR: 6.209, 95% CI: 2.393-16.114, P-value<0.001) were added. ST2 correlated with end of follow-up mortality (HR: 78.025, 95% CI: 7.592-801.926, P-value<0.001).

Conclusions: Elevated Gal-3 concentrations correlated with short-term rehospitalization, short-term mortality and end of follow-up mortality; whereas ST2 prognosticated end of follow-up mortality. Collective analysis with elevated NT-proBNP values further increased the outcomes’ risk. These results corroborate the assumption that promising novel biomarkers Gal-3 and ST2 could be valuable for HF risk stratification. We highlight that a multi-marker strategy added information, as a synergism between myocardial fibrosis biomarkers and the myocardial stretch peptide was observed.

Key Words: Acute decompensated heart failure; Short-term readmission; Short-term mortality; Galectin-3; ST2; NT-proBNP.

INTRODUCTION

Despite scientific advances HF short-term prognosis remains poor, as circa 25% of patients are readmitted in the first 30 days after hospital discharge and approximately 30% are readmitted 60 to 90 days post-discharge. Remarkably, the mortality rate 60 to 90 day post-discharge reaches 15%.

It urges to define a short-term prognosis for HF patients in order to reduce readmission and premature mortality. The actual treatment paradigm of HF is based, fundamentally, on the blockade of the renin-angiotensin-aldosterone system, nevertheless other mechanisms influence the genesis and progression of this syndrome.

The need for risk markers in precocious stages of the disease, in order to refrain its evolution, has led to an increasing interest in biomarkers related to the physiopathological pathways of HF, namely myocardial fibrosis. Myocardial fibrosis seems to favor left ventricular dysfunction which determines HF progression. Clinical judgement, the cornerstone of medical praxis is enhanced by imaging and biological diagnostic tests.

Fibrosis biomarkers emerge as promising tools that can complement traditional clinical practice by recognizing high risk patients that could benefit from therapeutic intensification and stricter surveillance. The role of natriuretic peptides as diagnostic predictors is undisputed, but Gal-3 and ST2 seem to be superior concerning prognosis.

In 2013, the ACA/ AHA recognized ST2 and Gal-3 as HF prognosticators, nevertheless the European Society of Cardiology (ESC) does not support this recommendation. Interestingly, a multi-marker strategy appears to yield additional information, as current data alludes a synergism between myocardial stretch peptides and fibrosis biomarkers.

MATERIAL AND METHODS

Study design and population

The pREDictors of Early REadmission IN Chronic hEart failure (REFERENCE) was an observational prospective cohort, single-center, single-arm study.

Correspondencia: luizmfaclaco@sapo.pt

Cópia da citação do arquivo: Barbosa M, MD, MSc; Matos A, MSc; Bicho M, MD, PhD; Menezes Falcão L, MD, PhD

Gal-3 y ST2 como biomarcadores: un paso al frente en el pronóstico de la Insuficiencia Cardíaca. Galicia Clin 2021; 82: 3: 146-151

Recibido: 10/01/2021; Aceptado: 25/02/21 // https://doi.org/10.22546/02/2454
Patients were recruited consecutively for a period of 12 months from an Internal Medicine ward.
Inclusion criteria were age ≥ 18 years old and hospitalization due to chronic decompensated HF patients in class III or IV of NYHA.
Exclusion criteria were:
1. in-hospital death in the first hospitalization;
2. hospital discharge against medical advice;
3. chronic kidney disease patients with a glomerular filtration rate (GFR) < 30 ml/min/1.73 m² (calculated with the Modification of Diet in Renal Disease score) or under renal replacement therapy;
4. moderate or severe hepatic impairment (calculated with the Child-Pugh score);
5. active neoplasm with or without metastasis.

The participation in the study was entirely voluntary and all eligible subjects signed the written informed consent.
The study was performed in conformity with its protocol, the Declaration of Helsinki and the Oviedo Convention. The study was approved by an Institutional Review Board (Academic Medical Center Ethics Committee).

Protocol and definitions
The diagnosis of HF was based on the ESC guidelines.10 Patient evaluation followed study protocol that included clinical history, physical examination, 12-lead electrocardiogram, thoracic X-ray, blood sampling for laboratory tests, transthoracic Doppler echocardiography and therapeutic data.
All echocardiograms M mode, two-dimensional and Doppler were performed by an experienced operator using a Hitachi Aloka afila 6 Medical device with a 2.5 MHz transducer.
Biochemical parameters were assessed as per routine using plasma samples.
Biomarkers were measured using plasma samples.
Plasma samples were stored at the study sites at -20°C, followed by storage at -80°C.
Galectin-3 and ST2/IL-33R were quantified in plasma using pre-coated human ELISA R&D Systems, Abingdon, USA kits.
Plasma NT-proBNP values were measured using electrochemiluminescence immunoassay Elecsys NT-proBNP Roche Diagnostics, GmbH, Mannheim, Germany.
In light of the European Society of Cardiology guidelines, HF with preserved ejection fraction (HFpEF) was defined as left ventricular ejection fraction (LVEF) ≥ 50%, midrange ejection fraction (HFmrEF) was defined as LVEF 40-49% and reduced ejection fraction (HFrEF) was defined as LVEF < 40%.10

Outcomes
We studied the correlation of Gal-3 and ST2 with short-term rehospitalization due to HF, short-term all-cause mortality and end of follow-up all-cause mortality in HF patients.

Short-term rehospitalization was defined as rehospitalization within 90 days of hospital discharge.
Short-term mortality was defined as death occurring within 90 days after hospital discharge.
End of follow-up mortality was defined as death that occurred during the entire study period.

Statistical analysis
Convenience sampling was used and no sample size calculation was performed. Categorical variables were summarized by relative and absolute frequencies and compared using the chi-squared test or Fisher’s Exact test.
Continuous variables were summarized by mean, standard deviation, median, first and third quartiles (Q1-Q3). Shapiro-Wilk test was used to assess the normality of continuous variables. Comparisons between patients with or without an event of interest were performed using the t-test or Wilcoxon Rank test, as applicable.

Short-term rehospitalization, short-term mortality and end of follow-up mortality were considered as stratification variables.
A survival analysis was performed for the events of interest.
For each endpoint, Kaplan-Meier survival estimates were calculated and plotted for each categorical variable. Log-rank tests were used to compare survival probabilities in each of the considered variables. A univariate Cox proportional hazards model was fitted to the data to obtain HR and 95% CI for each variable.
The proportional hazards assumption was tested using Schoenfeld residuals. All analyses were conducted at an overall significance level of 5%. No imputation was performed on missing data. No adjustments for multiplicity were performed.

Since there are no standardized cut-offs for Gal-3 and ST2, the multiclass AUCROC as defined by Hand and Till was used to evaluate the overall performance of each biomarker as a predictor of the outcomes.
Taking into consideration the low number of subjects, it was decided to consider as relevant predictors biomarkers that had an AUCROC above 0.7 and in which the 95% confidence interval did not contain 0.5 (value for which the predictor makes random guesses). The optimal cut-off value for each biomarker to predict each of the events was defined using the Youden Index, which maximizes the sensitivity and specificity of the predictor. Negative predictive values (NPV) and positive predictive values (PPV) were calculated and reported for the selected cut-offs.

RESULTS
From the 70 selected patients 5 were excluded from the analysis given that during follow-up they were diagnosed with active neoplasm.
The 65 patients who matched the selection criteria had a median follow-up period of 13.7 (6.7-18.9) months.
The mean age of the patients was 79.2 ± 10.8 years, 56.9% were female and their mean LVEF was 50.38 ± 19.07 %. Baseline characteristics of the population study are presented in Table 1. The 90-day post-discharge readmission percentage was 33.8% and the 90-day mortality was 18.5%. By the end of follow-up 40% of the patients had died.

**Spearman’s correlation coefficient**

Spearman’s correlation coefficient recognized an inversely proportional correlation between Gal-3 levels and baseline glomerular filtration rate (GFR) (Coefficient: -0.537, P-value<0.001) and admission GFR (Coefficient: -0.549, P-value<0.001).

In contrast, Spearman’s correlation revealed that Gal-3 and NT-proBNP values were proportional (Coefficient: 0.383, P-value=0.009), as depicted in Figure 1.

The same statistical method showed a significant negative correlation between ST2 levels and baseline GFR (Coefficient: -0.418, P-value<0.001) and admission GFR (Coefficient: -0.438, P-value<0.001).

**ROC analysis**

Regarding ROC analysis, for the short-term rehospitalization outcome, only Gal-3 had an acceptable AUCROC value (AUCROC: 0.74; CI95%: 0.55-0.92). For this biomarker, the optimal cut-off value (Youden Index) was 11.41 ng/mL with a high NPV (0.93) indicating a good capability in predicting (93% probability) that no short-term rehospitalization events occur if the biomarker is below the cut-off. The PPV was 0.54, being able to predict the event with a probability of 54%.

Concerning the short-term mortality outcome, there were two biomarkers with acceptable AUCROC values, Gal-3 (AUCROC: 0.85; CI95%: 0.74-0.97) and NT-proBNP (AUCROC: 0.75; CI95%: 0.58-0.92).

For Gal-3, the optimal cut-off value was 10.98 ng/mL with a perfect NPV (1.0), indicating an excellent capability in predicting (100% probability) that no short-term mortality events occur if the biomarker is below the cut-off. Regarding the capability of predicting short-term mortality events, the biomarker had inferior capabilities (PPV: 0.44), but it is still relevant enough to take it into consideration, given the 44% probability of the event to occur.

For NT-proBNP the optimal cut-off value was 21336 ng/L with a high NPV (0.91). The PPV was inferior (0.64), being able to predict with 64% probability an event of short-term death.

Minding the end of follow-up mortality outcome, we decided to consider Gal-3 and ST2 although they had an AUCROC slightly below 0.7 [Galactin-3 (AUCROC: 0.69; CI95%: 0.52-0.86) and ST2 (AUCROC: 0.69; CI95%: 0.53-0.85)], due to the fact that they had a significant behavior (95% confidence intervals above 0.5).

For Gal-3 the optimal cut-off value was 9.99 ng/mL with a NPV of 0.78 and PPV of 0.65. The ST2 biomarker had similar capabilities to Gal-3, with an optimal cut-off value of 24.79 ng/L with NPV of 0.83 and a PPV of 0.60.
Table 1. Baseline characteristics of the population study

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients (n=65)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>79.2 ± 10.8</td>
</tr>
<tr>
<td>Female Gender, n (%)</td>
<td>37 (56.9)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>58 (89.2)</td>
</tr>
<tr>
<td>Type 2 Diabetes, n (%)</td>
<td>25 (38.5)</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>41 (63.1)</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>17 (26.2)</td>
</tr>
<tr>
<td>Atrial Fibrillation, n (%)</td>
<td>28 (43.1)</td>
</tr>
<tr>
<td>Family History of CVD, n (%)</td>
<td>31 (47.7)</td>
</tr>
<tr>
<td>Tabagism, n (%)</td>
<td>21 (32.3)</td>
</tr>
<tr>
<td>Chronic Kidney Disease, n (%)</td>
<td>34 (52.3)</td>
</tr>
<tr>
<td>GFR (Baseline), median</td>
<td>57.8 (43.8 - 82.2)</td>
</tr>
<tr>
<td>GFR (Admission), median</td>
<td>47.9 (33.2 - 68.1)</td>
</tr>
<tr>
<td>Previous Acute Myocardial Infarction, n (%)</td>
<td>27 (41.5)</td>
</tr>
<tr>
<td>Hypertensive Heart disease, n (%)</td>
<td>44 (67.7)</td>
</tr>
<tr>
<td>Ischemic Heart disease, n (%)</td>
<td>22 (33.8)</td>
</tr>
<tr>
<td>Valvular Heart disease, n (%)</td>
<td>56 (86.2)</td>
</tr>
<tr>
<td>LVEF, mean (SD)</td>
<td>50.38 ± 19.07</td>
</tr>
<tr>
<td>NYHA class III, n (%)</td>
<td>43 (66.2)</td>
</tr>
<tr>
<td>ACE Inhibitor, n (%)</td>
<td>43 (66.2)</td>
</tr>
<tr>
<td>Beta Blocker, n (%)</td>
<td>38 (58.5)</td>
</tr>
<tr>
<td>Mineralocorticoid Receptor Antagonists, n (%)</td>
<td>19 (29.2)</td>
</tr>
<tr>
<td>Angiotensin II Receptor Blocker, n (%)</td>
<td>11 (16.9)</td>
</tr>
<tr>
<td>Loop Diuretic, n (%)</td>
<td>54 (83.1)</td>
</tr>
<tr>
<td>Dигoxin, n (%)</td>
<td>8 (12.3)</td>
</tr>
<tr>
<td>Galectin-3, median</td>
<td>9.82 (7.94 -12.00)</td>
</tr>
<tr>
<td>ST2, median</td>
<td>27.22 (15.45-44.39)</td>
</tr>
<tr>
<td>NT-proBNP (Admission), median</td>
<td>5701.0 (1867 - 11961)</td>
</tr>
</tbody>
</table>

Values are median (IQR), n (%), or mean ± SD.


Univariate Cox analysis

We acknowledged that Gal-3 ≥11.41 ng/mL correlated with short-term rehospitalization (HR: 11.762, 95% CI: 2.402-57.598, P-value=0.002). A link between Gal-3 ≥10.97 ng/mL and short-term mortality (HR: 13.731, 95% CI: 1.650-114.276, P value=0.015, Figure 2) and end of follow-up mortality (HR: 3.418, 95% CI: 1.345-8.689, P-value=0.010) was also identified. The association of NT-proBNP ≥21336 ng/L with Gal-3 ≥10.97 further increased the risk of short-term rehospitalization (HR: 11.985, 95% CI: 1.962-73.218, P value=0.007) and end of follow-up mortality (HR: 78.025, 95% CI: 7.592-801.926, P-value<0.001), as shown in Table 2.

A correlation between ST2 ≥24.78 ng/L and end of follow-up mortality was acknowledged (HR: 4.846, 95% CI: 1.396-16.825, P-value=0.013, Table 3).

If values of NT-proBNP ≥21336 ng/L were added to levels of ST2 ≥24.78 ng/L the risk augmented up to 6 times (HR: 5.953, 95% CI: 1.683-21.055, P-value=0.006) and if, instead, values of Gal-3 ≥9.99 ng/mL were considered the risk increased roughly to the same extent (HR: 6.209, 95% CI: 2.393-16.114, P-value<0.001, Table 3).

For the HFpEF subgroup the end of follow-up mortality risk for the combined values of ST2 ≥24.78 ng/L and Gal-3 ≥9.99 ng/mL was highest (HR: 15.782, 95% CI: 1.593-156.322, P-value=0.018) compared to the general population (HR: 6.209, 95% CI: 2.393-16.114, P-value<0.001) and the HFpEF subgroup (HR: 5.2, 95% CI: 1.223-22.187, P-value=0.026, Table 3).

DISCUSSION

Gal-3 is a soluble β-galactoside-binding protein which is produced by activated macrophages. It plays a pivotal role in cardiac fibroblast proliferation and collagen synthesis which result in left ventricular stiffness and ultimately in ventricular dysfunction.12

Although this acute and chronic inflammation marker is not specific of cardiac injury, since it has been involved in various organs fibrotic degeneration processes13 and even with ageing14 and tumor mediation15, the healthy heart expresses minimum amounts of Gal-3, which increases as HF progresses.16

Our finding that patients with renal impairment have higher Gal-3 levels is corroborated by various trials.17, 18, 19, 20

We are able to verify the assumption of numerous authors that patients with higher levels of Gal-3 have, also, higher levels of brain natriuretic peptides.6, 17, 18, 19, 20

In our research no correlation was identified between Gal-3 serum determinations and gender or LVEF, findings reminiscent of those of a sub analysis of the HF-ACTION study.21

Concerning NYHA functional class no correlation with Gal-3 was identified by us, likewise the sub analysis of the DEAL-HF and PRIDE HF trials.11, 17, 18, 22

Meijers WC et al. observed an association between elevated plasma Gal-3 and short-term readmission in HF23, which supports our results.

The role of Gal-3 as a predictor of short-term mortality is backed by the PRIDE sub analysis.11

The DEAL-HF trial enrolled NYHA functional class III and IV patients, a study population similar to ours, and recognized that Gal-3 was a reliable mortality predictor.18

A recent metanalysis also verified a correlation between Gal-3 and mortality.24

The sub analysis of the COACH trial, with a follow-up duration similar to ours, verified that Gal-3 was a predictor of the composite of all-cause mortality and HF hospitalization and that a multimarker strategy with NT-proBNP perfected risk stratification, which validates our findings.5

We emphasize that mortality risk related to Gal-3 decreased during follow-up which supports the premise that the first 90
days post-discharge implicate a maximum risk period that declines over time.

The pathophysiological role of ST2 in HF, is based in the cardioprotective effect of the interaction of its transmembrane receptor (ST2L) and its ligand, IL-33, a cytokine released in response to cardiomyocyte strain.\textsuperscript{25}

The duality IL-33/ST2L, participates in several inflammatory conditions, beyond cardiac distress, but although unspecific, it is expressed in cardiac fibroblasts and cardiomyocytes due to myocardial damage.\textsuperscript{25}

Its beneficial cardiac effect derives from the counterbalance of cardiac apoptosis, myocardial fibrosis, cardiomyocyte hypertrophy, and ultimately, by increasing myocardial function.\textsuperscript{25}

This advantageous effect is abrogated by the soluble isoform (sST2), which acts as a decoy receptor, by binding to IL-33 and blocking its signaling.\textsuperscript{25}

Thus, the rationale of using sST2 as HF biomarker relies on the fact that its levels are increased in cardiomyocyte damage, namely remodeling, fibrosis and hypertrophy.\textsuperscript{25}

Likewise several authors, we identified that ST2 levels vary inversely with the GFR.\textsuperscript{7, 26, 27}

As for age, as acknowledged by Rehman S et al.,\textsuperscript{7} no consistent correlation was identified in our investigation.

Our finding that heightened levels of ST2 predicted end of follow-up mortality is confirmed by the aforementioned study (the AUC ROC for mortality at 1 year was 0.71).\textsuperscript{7}

This conclusion is, also, sustained by the PRIDE trial, since a trend towards high concentrations of ST2 and one year-mortality was acknowledged.\textsuperscript{28}

Relevantly, the mutual quantification of ST2 and NT-proBNP improved risk stratification,\textsuperscript{28} as verified in our research. Similarly to Wang CH et al.,\textsuperscript{29} the combination of fibrosis biomarkers identified patients with higher risk of mortality. As expected end of follow-up mortality risk linked to ST2 and Gal-3 simultaneous quantification, was greatest in the HFrEF, which is a more vulnerable subgroup, and lowest in the HFpEF.

The weight of evidence suggests that Gal-3 and ST2 can be useful tools to detect and stratify high risk HF patients. Given their role in cardiac remodeling and consequently in the HF inexorable continuum, one must question if in a near future they will ascend as new cardiovascular therapeutic targets.

Due to the small sample size we did not perform multivariable analysis. Moreover, our research was a single-center study which may limit the extrapolation of our acknowledgments. Nevertheless, this study reports data from a real-world clinical background and the results are consistent with previously published large scale studies, therefore supporting the validity of our findings.

**CONCLUSIONS**

Elevated Gal-3 concentrations correlated with short-term rehospitalization, short-term mortality and end of follow-up mortality; whereas ST2 prognosticated end of follow-up mortality.

These results corroborate the assumption that promising novel biomarkers Gal-3 and ST2 could be valuable for HF risk stratification.
We highlight that a multi-marker strategy added information, as a synergism between myocardial fibrosis biomarkers and NT-proBNP was observed.

REFERENCES


